Elk Grove Village, Il.–July 13, 2018– RiMO Therapeutics Inc., a privately held oncology drug development company and a pioneer in Radio-immuno Metal-Organic (RiMO) technology-based cancer immunotherapy, today announced that the first patient has been dosed in a Phase 1 study of RiMO-301 in patients with advanced tumors. RiMO-301 enhances the efficacy of X-ray radiotherapy via the unprecedented radiotherapy-radiodynamic therapy (RT-RDT) mode of action.
“Initiation of this study represents not only a significant milestone for RiMO Therapeutics but also the field of nanoscale metal-organic frameworks (nMOFs), as RiMO-301 is the first nMOF-based product to enter clinical trials.” said Wenbin Lin, Ph.D., founder and chairman of RiMO and also the James Franck Professor of Chemistry, Radiation & Cellular Oncology, and the Ludwig Center for Metastasis Research at the University of Chicago. “Most importantly, we believe this program has the potential to change the treatment paradigm for some cancer types and significantly benefit patients.”
Dr. Lin and coworkers have recently published groundbreaking research on the synergistic effect when combining nMOFs with cancer immunotherapy (Nat. Biomed. Eng., doi:10.1038/s41551-018-0203-4). “We expect that this study will generate important insights about the safety of RiMO-301 with radiation and the potential to enhance therapeutic efficacy in the patient population for whom radiotherapy is only palliative.” said Jason Luke, M.D., University of Chicago Medicine.
About the Study
The Phase 1 study is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. The primary objectives in the study include determining maximum tolerated dose (MTD), pharmacokinetics and preliminary anti-tumor activity of RiMO-301. Please refer to www.clinicaltrials.gov for additional clinical trial details.
About RiMO Therapeutics Inc.
RiMO Therapeutics Inc. is a privately held oncology drug development company that aims to address unmet medical needs and improve patient care. Its nMOF technology is in-licensed from the University of Chicago with worldwide rights in development and commercialization. For more information, please visit our website at www.rimorx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding RiMO’s expectations and beliefs about the potential benefits of RiMO’s product candidate RiMO-301, the plans and timelines for the clinical development and the benefit of its strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from RiMO’s current expectations and beliefs. For example, there can be no guarantee that any product candidate RiMO is developing will successfully commence or complete necessary clinical development phases, or that development of any of RiMO’s product candidates will successfully continue. Management’s expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors including but not limited to RiMO’s results of clinical trials; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; RiMO’s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; RiMO’s ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. Any forward-looking statements contained in this press release speak only as of the date hereof, and RiMO expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: RiMO Therapeutics Inc.
Media Contact: Dr. Wenbin Lin, email@example.com